<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35020823</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1207</StartPage><EndPage>1210</EndPage><MedlinePgn>1207-1210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awab472</ELocationID><Abstract><AbstractText>Several genetically-targeted therapies are being developed for ALS. Research is increasingly supportive of a greater incidence of clinically actionable variants in sporadic ALS than previously reported. Salmon <i>et al</i>. outline the need to improve access, and offer genetic testing to all people diagnosed with ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Kristiana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9054-026X</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seung H</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0001-9644-9598</Identifier><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, Hanyang University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-0094-5429</Identifier><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9579-5341</Identifier><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience 'Rita Levi Montalcini', University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, AOU Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0002-6559-3965</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Laboratory for Neurobiology, KU Leuven and Center for Brain and Disease Research, VIB, Leuven Brain Institute, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lillo</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7398-7203</Identifier><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a Sur, Facultad de Medicina, Universidad de Chile and Geroscience Center for Brain Health and Metabolism, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-3474-7140</Identifier><AffiliationInfo><Affiliation>The Eleanor and Lou Gehrig ALS Center, The Neurological Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>17</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35020823</ArticleId><ArticleId IdType="pmc">PMC9129091</ArticleId><ArticleId IdType="doi">10.1093/brain/awab472</ArticleId><ArticleId IdType="pii">6501632</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2002;(2):CD001447.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076411</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872907</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH. The beginning of genomic therapies for ALS. N Engl J Med. 2020;383(2):180&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640137</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Al-Chalabi A, Chio A, et al. . Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry. 2017;88(12):1042&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11):603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone B, Conforti FL. Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: how common are common mutations in ALS genes? Expert Rev Mol Diagn. 2020;20(7):703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">32497448</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z-Y, Zhou Z-R, Che C-H, Liu C-Y, He R-L, Huang H-P. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrizaila N, Sobue G, Kuwabara S, et al. . Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016;87(8):821&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">27093948</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered. 2011;71(4):281&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">21846995</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A. Perspective: Don&#x2019;t keep it in the family. Nature. 2017;550(7676):S112.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045374</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13(2):96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Bede P, Elamin M, et al. . Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12(3):157&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208036</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Dahlberg C, Birve A, Veldink JH, van den Berg LH, Andersen PM. Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(5):562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965850</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Fifita JA, Vucic S, et al. . Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry. 2013;84(8):931&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. . Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS . Accessed 20 October 2021. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-tofersen-phase-3-study-and-its</Citation></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Battistini S, Calvo A, et al. . Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry. 2014;85(5):478&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. . Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith C, Abrahao A, Benstead T, et al. . Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020;192(46):E1453&#x2013;E1468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683000</ArticleId><ArticleId IdType="pubmed">33199452</ArticleId></ArticleIdList></Reference><Reference><Citation>
Motor Neuron Disease: assessment and management&#x2014;Clinical Guideline . Accessed 20 October 2021. https://www.nice.org.uk/guidance/ng42/documents/motor-neurone-disease-full-guideline2</Citation></Reference><Reference><Citation>Andersen PM, Borasio GD, Dengler R, et al. . Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler. 2007;8(4):195&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653917</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, et al. . EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2014;revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajda A, McLaughlin RL, Heverin M, et al. . Genetic testing in ALS: A survey of current practices. Neurology. 2017;88(10):991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333513</ArticleId><ArticleId IdType="pubmed">28159885</ArticleId></ArticleIdList></Reference><Reference><Citation>Klepek H, Nagaraja H, Goutman SA, Quick A, Kolb SJ, Roggenbuck J. Lack of consensus in ALS genetic testing practices and divergent views between ALS clinicians and patients. Amyotroph Lateral Scler Frontotemporal Degener 2019;20(3&#x2013;4):216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7085941</ArticleId><ArticleId IdType="pubmed">30931630</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Doyle C, Chio A, Traynor BJ. Use of genetic testing in amyotrophic lateral sclerosis by neurologists. JAMA Neurol. 2017;74(1):125&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112760</ArticleId><ArticleId IdType="pubmed">27893008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanby MF, Scott KM, Scotton W, et al. . The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain. 2011;134(Pt 12):3454&#x2013;3457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235555</ArticleId><ArticleId IdType="pubmed">21933809</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Parker MD, Cooper-Knock J, et al. . Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassano M, Calvo A, Moglia C, et al. . Mutational analysis of known ALS genes in an Italian population-based cohort. Neurology. 2021;96(4):e600&#x2013;e609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905787</ArticleId><ArticleId IdType="pubmed">33208543</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, et al. . Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology. 2021:55(5)342&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">34247168</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson PA, Ernhill K, Andersen PM, et al. . Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain. 2004;127(Pt 1):73&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">14534160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekhtiari Bidhendi E, Bergh J, Zetterstrom P, et al. . Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathol. 2018;136(6):939&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280858</ArticleId><ArticleId IdType="pubmed">30284034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski KJ, Minikel EV, et al. . Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K, Oh KW, Nordin A, et al. . De novo mutations in SOD1 are a cause of ALS. J Neurol Neurosurg Psychiatry. 2022;93(2):201&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784989</ArticleId><ArticleId IdType="pubmed">34518333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J. Implications of confirmed de novo pathogenic SOD1 mutations. J Neurol Neurosurg Psychiatry. 2022;93(2):118.</Citation><ArticleIdList><ArticleId IdType="pubmed">34599043</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH. ALS genetic epidemiology &#x2018;How simplex is the genetic epidemiology of ALS?&#x2019;. J Neurol Neurosurg Psychiatry. 2017;88(7):537.</Citation><ArticleIdList><ArticleId IdType="pubmed">28209650</ArticleId></ArticleIdList></Reference><Reference><Citation>Erazo D, Luna J, Preux PM, Boumediene F, Couratier P. Epidemiological and genetic features of amyotrophic lateral sclerosis in Latin America and the Caribbean: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1-2):4&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">33871294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>